Back to Stocks

CLOV

CLOVER HEALTH INVESTMENTS, CORP. /DE
7 filings tracked
healthcarehealth insuranceSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Clover Health has reached a pivotal financial inflection point, transitioning from a cash-burning growth stage to a profitable, self-sustaining enterprise. The first quarter of 2026 was marked by a massive 63% year-over-year surge in revenue, reaching $749.2 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline shift to profitability, a closer examination of the balance sheet reveals significant structural vulnerabilities. The most pressing concern is the rapid expansion of unpaid claims, which ballooned 70% year-over-year to $260.4 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CLOV filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between successful scaling and systemic risk. On one hand, the growth in membership and the achievement of GAAP profitability suggest that Clover's technology-led approach to Medicare Advantage is gaining traction. The shift to positive operating cash flow is a major milestone that reduces the immediate need for dilutive capital raises. However, the divergence between reported net income and the swelling liability of unpaid claims creates a tension that investors must weigh carefully. The true test for Clover will be its ability to maintain the 4.0 Star Rating and navigate the upcoming wave of CMS audits without eroding its modest capital cushion. The long-term valuation will likely depend on whether the Counterpart Health SaaS transition can materialize into a meaningful revenue stream, diversifying the business away from the regulatory volatility of the insurance market.

Selected Quarter

Core Takeaway

Clover has proven its business model can scale and generate profit, but the quality of that profit is questioned by a 70% increase in unpaid claims reserves.

Investor Lens

The trade-off is between the proven ability to grow and profit versus the systemic risk of the insurance reserve 'black box'.

Watch Next

CMS RADV audit outcomes and the revenue contribution growth from Counterpart Health.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.15Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 8

Company flipped from a net loss to a GAAP net income of $27.3 million.

earnings beat
90%
bullishMay 8

Adjusted SG&A as a percentage of revenue compressed from 18.0% to 15.9%.

margin expansion
70%
bearishMay 8

Significant stock-based compensation expense continues to impact the bottom line.

dilution risk
40%
bearishMay 8

Exposure to CMS RADV audits and risk-adjustment policy changes creates potential liability.

regulatory action
60%
bullishMay 8

Company flipped from a net loss to a GAAP net income of $27.3 million.

earnings beat
90%
bullishMay 8

Adjusted SG&A as a percentage of revenue compressed from 18.0% to 15.9%.

margin expansion
70%
bearishMay 8

Significant stock-based compensation expense continues to impact the bottom line.

dilution risk
40%
bearishMay 8

Exposure to CMS RADV audits and risk-adjustment policy changes creates potential liability.

regulatory action
60%
bullishMay 8

Company flipped from a net loss to a GAAP net income of $27.3 million.

earnings beat
90%
bullishMay 8

Adjusted SG&A as a percentage of revenue compressed from 18.0% to 15.9%.

margin expansion
70%
bearishMay 8

Significant stock-based compensation expense continues to impact the bottom line.

dilution risk
40%
bearishMay 8

Exposure to CMS RADV audits and risk-adjustment policy changes creates potential liability.

regulatory action
60%
bullishMay 8

Company flipped from a net loss to a GAAP net income of $27.3 million.

earnings beat
90%
bullishMay 8

Adjusted SG&A as a percentage of revenue compressed from 18.0% to 15.9%.

margin expansion
70%
bearishMay 8

Significant stock-based compensation expense continues to impact the bottom line.

dilution risk
40%
bearishMay 8

Exposure to CMS RADV audits and risk-adjustment policy changes creates potential liability.

regulatory action
60%
bullishMay 8

Company flipped from a net loss to a GAAP net income of $27.3 million.

earnings beat
90%
bullishMay 8

Adjusted SG&A as a percentage of revenue compressed from 18.0% to 15.9%.

margin expansion
70%
bearishMay 8

Significant stock-based compensation expense continues to impact the bottom line.

dilution risk
40%
bearishMay 8

Exposure to CMS RADV audits and risk-adjustment policy changes creates potential liability.

regulatory action
60%
bullishMay 8

Company flipped from a net loss to a GAAP net income of $27.3 million.

earnings beat
90%
bullishMay 8

Adjusted SG&A as a percentage of revenue compressed from 18.0% to 15.9%.

margin expansion
70%
bearishMay 8

Significant stock-based compensation expense continues to impact the bottom line.

dilution risk
40%
bearishMay 8

Exposure to CMS RADV audits and risk-adjustment policy changes creates potential liability.

regulatory action
60%
bullishMay 8

Company flipped from a net loss to a GAAP net income of $27.3 million.

earnings beat
90%
bullishMay 8

Adjusted SG&A as a percentage of revenue compressed from 18.0% to 15.9%.

margin expansion
70%
bearishMay 8

Significant stock-based compensation expense continues to impact the bottom line.

dilution risk
40%
bearishMay 8

Exposure to CMS RADV audits and risk-adjustment policy changes creates potential liability.

regulatory action
60%

Filing History

10-QMay 8, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads between successful scaling and systemic risk. On one hand, the growth in membership and the achievement of GAAP profitability suggest that Clover's technology-led approach to Medicare Advantage is gaining traction. The shift to positive operating cash flow is a major milestone that reduces the immediate need for dilutive capital raises. However, the divergence between reported net income and the swelling liability of unpaid claims creates a tension that investors must weigh carefully. The true test for Clover will be its ability to maintain the 4.0 Star Rating and navigate the upcoming wave of CMS audits without eroding its modest capital cushion. The long-term valuation will likely depend on whether the Counterpart Health SaaS transition can materialize into a meaningful revenue stream, diversifying the business away from the regulatory volatility of the insurance market.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.